comparemela.com

Latest Breaking News On - Lei liu - Page 5 : comparemela.com

China Jo-Jo Drugstores Receives Government Quality Award

/PRNewswire/ China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor.

Frank zhaoTina xiaoExchange commissionPrnewswire china jo drugstores incCompany contactChina jo drugstores incAscent investor relationsJo drugstoresGovernment quality awardGongshu districtGovernment qualityLei liuHealthy chinaChina jo drugstoresRelations contact

China Jo-Jo Drugstores Receives 2021 China ESG Golden Awards- Sustainability Award from Sina Finance

/PRNewswire/ China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor.

Frank zhaoTina xiaoCompany contactChina life insurance companyChina jo drugstores incExchange commissionAscent investor relationsShanghai fosun pharmaceutical co ltdChina jo drugstoresSina financeSustainability awardCommercial bankLei liuJo drugstoresRelations contact

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

/PRNewswire/ Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for.

Inner mongoliaNei mongolSouth africaLinqi zhangBrii bioRogers luoUs national institute of healthClinical trial groupDrug administrationNational clinical research centerGlobal healthBrii biosciencesNational medical products administrationInfectious diseases research centerTsinghua universityUse authorization

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

/PRNewswire/ Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for.

Inner mongoliaNei mongolSouth africaLinqi zhangBrii bioRogers luoUs national institute of healthClinical trial groupDrug administrationNational clinical research centerGlobal healthBrii biosciencesNational medical products administrationInfectious diseases research centerTsinghua universityUse authorization

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | Critical Care Medicine | JAMA

This case series describes clinical outcomes in 5 Chinese patients with laboratory-confirmed COVID-19, ARDS, and high viral loads despite antiviral treatment wh

Zheng zhangYan yangYingxia liuTechnology researchNational natural science foundation of chinaChina postdoctoral science foundationDrug administrationWorld health organizationNational scienceGeneodx coTechnology majorKey technology rd program of tianjinGeneodx co ltdSequential organ failure assessmentMiddle eastShenzhen third people

vimarsana © 2020. All Rights Reserved.